ClinicalTrials.gg
CompletedNCT05727943CLIOKIDUpdated Oct 20, 2026

Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study

A Phase 2 interventional study of Clioquinol in Epilepsy Intractable, sponsored by KU Leuven. Completed at 1 site in Belgium. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by KU Leuven · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2022, registered Dec 2022).
Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Drug Resistant Epilepsy with a site in Belgium — 5 open to participants now, 6 under way, 1 of them phase 3. Drug Resistant Epilepsy · Belgium.

Enrollment
14th of 15
10 · median 40
Started
2022
with 1 other
Phase 2
4 of 17
1 open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
KU Leuven

Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 2, and was the 10th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

5 of the 17 studies in Drug Resistant Epilepsy with a site in Belgium are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Drug Resistant Epilepsy with a site in Belgium, or all of them as a file.
02

Study summary

In this exploratory trial, the potential anti-seizure activity of clioquinol in a small cohort of adolescents with drug-resistant epilepsy will be examined. Subjects will be exposed to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose). The main hypothesis of the study is that 30% of the included subjects will be responders and that the median seizure frequency reduction will be at least 30%.

Read the detailed description

In this exploratory phase 2 trial, adolescents with DRE will be exposed to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose). During the trial concomitant anti-epileptic medication will be kept stable, so that only the add-on effect of clioquinol will be assessed. During a prospective baseline of 2 weeks, the number of seizures will be counted. The effect of first low dose (1mg/kg/day) and later higher dose (4mg/kg/day) of clioquinol on seizure frequency will be calculated using the typical epilepsy trial outcome measures: percent reduction of seizure frequency and number of patients with a >50% seizure frequency reduction ('responders').

PK samples will be collected in the first 4 patients pre-dose and 2, 4 and 8 hours post-dose, both at initiation of the lower dose (1mg/kg/day) and the higher dose (4mg/kg/day) and on visit 4. The obtained PK data will be compared with the available literature data. Since we cannot define 'absolute' PK values (yet), we use a relative stopping rule in this first phase. If >1 of the first 4 patients show a PK pattern which is more than 50% different (max PK values 50% above literature max values), the study will be ended in these 4 patients. If the dosages need to be changed for the following patients, a protocol amendment will be provided to the FAGG and the EC. In the following subjects, a simplified PK study will be done at both dosages to examine whether they follow the findings in the 4 exploratory patients. Here also, a stopping rule when the PK data is more than 50% higher than the PK data obtained in the first 4 patients will be used.

Not only the effect of the drug on seizure frequency will be calculated, but also the effect on seizure severity, overall impact of seizures, medication side effects, comorbidities, and overall QoL, using standardized questionnaires (NHS3 and PIES) (1, 2).

The main hypothesis of the study is that 30% of the included patients will be responders and that the median seizure frequency reduction will be at least 30%. These numbers are based on very similar trial results with new anti-epileptic drugs in drug-resistant childhood epilepsy.

03

Conditions studied

  • Epilepsy Intractable
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this Trial must meet all of the following criteria:

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures
  2. In females with child bearing potential: negative pregnancy test or use of highly effective methods of ; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some intra-uterine devices, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomized partner
  3. Age ≥ 12 years and \< 18 years at time of inclusion
  4. Weight ≥ 20 kg at time of inclusion
  5. Well defined epilepsy history with convulsive seizures (with observable and countable motor component)
  6. Drug-resistant epilepsy: before inclusion failure of at least 2 AEDs
  7. Drug-resistant epilepsy: ≥ 4 seizures in the 2 week prospective period (baseline) before visit 2, not all (4) seizures observed in 1 of the 2 weeks. Baseline period can be extended with 1 or 2 weeks.
  8. The patient is at the moment of inclusion on max 3 anti-epileptic drugs (VNS and ketogenic diet not included)

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history of liver or kidney disease. Children with a co-existing active neuropathy (such as neuritis optica, transverse myelitis)
  2. Asian ethnicity
  3. Abnormal low blood level of vitamin B12 or Zn
  4. Patients with hypothyroidism
  5. Any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol
  6. Any prior or concomitant treatment(s) that might jeopardize the participant's safety or that would compromise the integrity of the Trial
  7. Exposure to clioquinol before the trial
  8. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate, highly effective
  9. Participation in an interventional Trial with an IMP or device
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    add - on clioquinol

    Add-on clioquinol to concomitant anti seizure medications. Clioquinol - magistral suspension preparation (100mg/ml) - oral intake Exposure 2 weeks to low dose: 1 mg/kg/day Exposure 6 weeks to higher dose: 4 mg/kg/day

    Drug: Clioquinol

Interventions

  • add on clioquinol to concomitant ASM

06

What researchers measure

Primary outcomes

  1. Responder rate : seizure frequency reduction

    Percentage of 50% responders after 2 weeks and 6 weeks exposure to low (1mg/kg/day) and higher doses (4mg/kg/day) of clioquinol respectively

    Time frame: 8 weeks intervention

Secondary outcomes

  1. safety and Quality of Life assessment

    Safety during trial (systematic recording of adverse events) .

    Time frame: 8 weeks intervention

07

Study locations

1 site
  • University Hospitals UZ Leuven
    Leuven, 3000, Belgium
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2022 to primary completion in Oct 2026, 55 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2023 → Oct 2026 and completion Dec 2023 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2022
First posted
Feb 14, 2023
StartActual
Mar 1, 2022
Primary completionActual
Oct 1, 2026was Dec 2023
CompletionActual
Oct 1, 2026was Dec 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 20, 2026
Primary completion
Dec 31, 2023→Oct 1, 2026 (actual)
Oct 20, 2026
Study completion
Dec 31, 2023→Oct 1, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Status unknown→Completed
    Primary completion Dec 31, 2023→Oct 1, 2026 (now actual)
    Study completion Dec 31, 2023→Oct 1, 2026 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05727943
Lead sponsor
KU Leuven
Responsible party
Lieven Lagae (Principal Investigator, KU Leuven) — Principal investigator
First posted
Feb 14, 2023
Start date
Mar 1, 2022
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Oct 20, 2026

Study contacts

Lieven Lagae, MD PhD
principal investigator · University Hospitals, University of Leuven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clioquinol

Start the discussion